Business ❯ Pharmaceutical Industry

Drug Manufacturing

Pricing Strategies Quality Control Regulatory Compliance Investment Generic Drugs Market Competition Supply Chain Management Cost Management Investment Strategies Supply Chain Issues Novo Nordisk Market Dynamics Export Regulations Illegal Trade Market Regulation Product Safety Quality Assurance Quality Standards Market Trends Compounding Pharmacies Compliance Market Launch Cost Reduction Eli Lilly Illegal Operations Market Regulations Product Integrity Generic Drug Production Generic Drug Market Legal Issues Purdue Pharma Corporate Responsibility Counterfeit Products Market Access Packaging Errors Licensing Onshoring Bayer Market Supply Cost Structures HLB Pharma Group Generic Pharmaceuticals Domestic Production Drug Pricing Strategies Illegal Pharmaceuticals Specialty Pharmacy Surya Prabha Pharma Chem Rusan Pharma Limited Over-the-Counter Medications Production Challenges Pain Relief Medications WuXi AppTec Foreign Corporations Product Safety Issues Compounding Facilities Economic Initiatives Market Impact Biosimilars Price Negotiations Mifepristone Production Companies Regulations Pharmaceutical Companies Corporate Acquisitions Market Approval Distribution Practices Compounded Medications Market Strategies Sresan Pharma Contract Development Patent Laws Investment Decisions Generic Drug Companies Amgen Product Recall Legal Defense Brand Management Nimesulide AstraZeneca Production Issues International Trade Generic Medications Research and Development Generic Drugmakers Contract Drugmakers Pricing Agreements Hormone Therapy Products Illegal Sales Eli Lilly and Co. Pfizer Compliance Regulations Perrigo Company Warnings Market Entry Compounding Pharmacy Product Recalls Product Legitimacy Product Authenticity Counterfeit Drug Sales Supply Chain

Daraxonrasib Doubles Survival in Phase 3 Trial of Treated Metastatic Pancreatic Cancer

An oral KRAS inhibitor that raised median survival to 13.2 months is now available through an FDA expanded access program pending formal review

Supreme Court Clears Path for Generic 'Skinny Labels' in Unanimous Hikma Ruling

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

White House Projects $529 Billion in Savings From Trump’s MFN Drug Pricing Plan

FDA Proposes Blocking Bulk Compounding of GLP-1 Drugs by Outsourcing Facilities

Trump Seals Regeneron Drug-Pricing Pact, Completing 17-Company Push

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Indian National Sentenced to 43 Months for Counterfeit Keytruda Scheme

TrumpRX.gov Launches With 40+ Lower-Priced Drugs as Companies Announce Cuts

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Chicago Nurse Pleads Not Guilty to Federal Charges Over Counterfeit ‘Ozempic’ Injections

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

FDA Fast-Tracks Augmentin XR in First Approval Under National Priority Voucher Pilot

First Lenacapavir Shipments Reach Zambia and Eswatini as U.S. Excludes South Africa From Donated Doses

RFK Jr. To Announce New HHS Plan To Cut U.S. Drug Prices Today

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

AstraZeneca Strikes White House Drug-Price Deal, Wins Three-Year Tariff Reprieve

TrumpRx–Pfizer Drug-Price Deal Leaves Key Details Unclear

White House Clinches Pfizer Pricing Deal Tied to Tariff Reprieve and $70 Billion U.S. Investment